Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases

Clinical Biochemistry

Volumn 44, Issue 10-11, 2011, Pages 884-888

  Park, Yongjung ^a   Lee, Jong Han ^a   Hong, Duck Jin ^a   Lee, Eun Young ^a   Kim, Hyon Suk ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

CA125; Human epididymal secretory protein E4; Ovarian cancer; Tumor markers

Indexed keywords

CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4; TUMOR MARKER;

ARTICLE; CHRONIC KIDNEY DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; GYNECOLOGIC DISEASE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OVARY CANCER; PREGNANCY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

CA-125 ANTIGEN; DIAGNOSIS, DIFFERENTIAL; EPIDIDYMAL SECRETORY PROTEINS; FEMALE; HUMANS; OVARIAN NEOPLASMS; ROC CURVE;

EID: 79958817864     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.04.011     Document Type: Article

References (28)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Earle C.C., Schrag D., Neville B.A., et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 2006, 98:172-180.
3. Schink J.C. Current initial therapy of stage III and IV ovarian cancer: challenges for managed care. Semin Oncol 1999, 26:2-7.
4. Rosen D.G., Wang L., Atkinson J.N., et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 2005, 99:267-277.
5. Maggino T., Gadducci A., D'Addario V., et al. Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Gynecol Oncol 1994, 54:117-123.
6. Kobayashi H., Yamada Y., Sado T., et al. A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int J Gynecol Cancer 2008, 18:414-420.
7. Bast R.C. Status of tumor markers in ovarian cancer screening. J Clin Oncol 2003, 21:200-205.
8. Gadducci A., Ferdeghini M., Prontera C., et al. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis. Gynecol Oncol 1992, 44:147-154.
9. Kim J.H., Skates S.J., Uede T., et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002, 287:1671-1679.
10. Healy D.L., Burger H.G., Mamers P., et al. Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors. N Engl J Med 1993, 329:1539-1542.
11. Yousef G.M., Polymeris M.E., Yacoub G.M., et al. Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res 2003, 63:2223-2227.
12. Hellstrom I., Raycraft J., Hayden-Ledbetter M., et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003, 63:3695-3700.
13. Drapkin R., von Horsten H.H., Lin Y., et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005, 65:2162-2169.
14. Moore R.G., Brown A.K., Miller M.C., et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008, 108:402-408.
15. Havrilesky L.J., Whitehead C.M., Rubatt J.M., et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol 2008, 110:374-382.
16. Scholler N., Crawford M., Sato A., et al. Bead-based ELISA for validation of ovarian cancer early detection markers. Clin Cancer Res 2006, 12:2117-2124.
17. Kobel M., Kalloger S.E., Boyd N., et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008, 5:e232.
18. Galgano M.T., Hampton G.M., Frierson H.F. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 2006, 19:847-853.
19. Bingle L., Cross S.S., High A.S., et al. WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir Res 2006, 7:61.
20. Xi Z., LinLin M., Ye T. Human epididymis protein 4 is a biomarker for transitional cell carcinoma in the urinary system. J Clin Lab Anal 2009, 23:357-361.
21. Li J., Dowdy S., Tipton T., et al. HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn 2009, 9:555-566.
22. Moore R.G., Brown A.K., Miller M.C., et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol 2008, 110:196-201.
23. Halila H., Stenman U.H., Seppala M. Ovarian cancer antigen CA 125 levels in pelvic inflammatory disease and pregnancy. Cancer 1986, 57:1327-1329.
24. Sarandakou A., Kontoravdis A., Kontogeorgi Z., Rizos D., Phocas I. Expression of CEA, CA-125 and SCC antigen by biological fluids associated with pregnancy. Eur J Obstet Gynecol Reprod Biol 1992, 44:215-220.
25. Niloff J.M., Knapp R.C., Schaetzl E., Reynolds C., Bast R.C. CA125 antigen levels in obstetric and gynecologic patients. Obstet Gynecol 1984, 64:703-707.
26. Haga Y., Sakamoto K., Egami H., Yoshimura R., Akagi M. Evaluation of serum CA125 values in healthy individuals and pregnant women. Am J Med Sci 1986, 292:25-29.
27. Moore R.G., McMeekin D.S., Brown A.K., et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009, 112:40-46.
28. Andersen M.R., Goff B.A., Lowe K.A., et al. Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol 2010, 116:378-383.